LWBK1006-30 LWW-Govindan-Review December 12, 2011 19:35
Chapter 30•Lymphomas 427Question 30.50. All of the following statements about new treatment modalities in HL are
true, EXCEPT:
A. Vinorelbine, idarubicin, and gemcitabine have been found to have
activity in HL.
B. Native monoclonal antibodies have been tested in HL: CD20-based
antibodies are not active in LPHL.
C. Anti-CD30 antibodies and bispecific anti-CD30 antibodies
(CD16/CD30; CD30/CD64) are currently under development.
D. In EBV-positive HL, mostly LMP2a-specific autologous cytotoxic
CD8 T cells have been generated in vitro and shown to be active
in vivo.Question 30.51. All of the following statements about novel therapies are true, EXCEPT:
A. SGN-35 (brentuximab vedotin) is active in both Hodgkin’s disease
and anaplastic large cell lymphoma.
B. SGN-35 is an antibody-drug conjugate combining an anti-CD30 anti-
body with a synthetic antimitotic agent monomethyl auristin that
enhances its antilymphoma activity as compared to SGN-30 that con-
sists of the anti-CD30 antibody alone.
C. CD30 is expressed only in ALK-positive anaplastic large cell lym-
phoma and Hodgkin’s disease.
D. Lenalinomide (a thalidomide-derivative immune modulator), panabi-
nostat (a histone deacetylase class I and II inhibitor), and everolimus
(an mTOR inhibitor) have shown activity in Hodgkin’s disease and
are currently under development for relapsed disease and for main-
tenance after autologous stem cell transplantation.